Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Survival After SARD-ILD Exacerbation Differs by Race/Ethnicity
A retrospective review of 46 patients hospitalized for acute exacerbations of systemic autoimmune‑related interstitial lung disease (SARD‑ILD) found marked racial disparities in long‑term outcomes. Black patients experienced the highest 1‑year mortality at 55%, while white patients had the lowest at 31%; transplant rates also favored white patients (46% of transplants) over Black patients (17%). In‑hospital metrics such as mortality, ventilation, ICU admission and antifibrotic use did not differ by race. The findings suggest structural inequities affecting post‑discharge care and access to transplantation.
Pegtarazimod Improves Oxygen Use in Acute COPD Exacerbation
Phase 2a data presented at the American Thoracic Society meeting show that pegtarazimod, an anti‑inflammatory peptide, improved oxygen utilization and lung‑function metrics in hospitalized adults with acute COPD exacerbations. In a double‑blind trial of 21 patients, the 10‑person pegtarazimod arm reduced...
Kazia’s Paxalisib Shows >50% CTC Drop, Early Responses
Kazia Therapeutics ($KZIA) is a catalyst-driven setup centered on upcoming ASCO data from their Paxalisib drug development platform. The update is following earlier disclosures from their ongoing Phase 1b ABC-Pax study evaluating paxalisib in metastatic triple-negative breast cancer (TNBC) showing...
Why Clinician-Led AI Strategies Are Gaining Momentum in Healthcare
Presbyterian Healthcare Services has placed a practicing nurse practitioner, Lori Walker, as its chief medical information officer to lead its AI transformation, emphasizing a clinician‑led strategy. Walker’s frontline experience lets her evaluate AI tools against real workflow constraints, fostering trust...
Developing a Drug To Reverse Heart Disease
Repair Biotechnologies’ lead candidate, REP-0004, is an mRNA‑based lipid nanoparticle designed to deliver a cholesterol‑degrading protein exclusively to hepatocytes. The FDA granted the drug orphan‑drug status and the company targets a Phase 1 start by mid‑2027, pending GMP manufacturing and IND‑enabling...
Design Therapeutics to Unveil RESTORE-FA Gene Therapy Data as Shares Edge Higher
Design Therapeutics (DSGN) announced a webcast on May 18, 2026, to present Phase 1/2 RESTORE-FA trial data for its DT‑216P2 gene‑therapy candidate targeting Friedreich's ataxia. The move has drawn heightened investor attention as the company seeks to prove its novel...
Texas Children’s Hospital Pays $10 Million, Ends Gender‑Transition Care for Minors
The U.S. Department of Justice and Texas Attorney General Ken Paxton reached a settlement with Texas Children’s Hospital that includes a $10 million payment, a ban on gender‑transition procedures for minors, and the creation of the nation’s first detransition clinic. The...
Merck's China-Licensed ADC Succeeds in First Global Trial
Merck ADC, licensed from China, hits mark in first big global trial https://t.co/tAvLkw6pYm @ByJonGardner $MRK $GILD $AZN
Genentech Secures FDA Approval for Tecentriq in Muscle‑Invasive Bladder Cancer
Roche’s Genentech has won U.S. FDA approval for its immunotherapy Tecentriq as an adjuvant treatment for patients with muscle‑invasive bladder cancer guided by circulating tumor DNA. The decision adds a new therapeutic line for a disease with limited options and...
Reclaiming the Lost Art of the Physical Exam
Ann Lebeck’s essay warns that modern medicine’s focus on imaging and referrals is eclipsing the foundational skill of careful physical observation. She argues that subtle cues—gait, posture, guarded movements—often precede diagnostic findings and can guide more accurate, cost‑effective care. While technology...
Opioid Use Duration Should Be Reduced After Ocular Surgery: Anton Kolomeyer, MD, PhD
A 2019 JAMA Ophthalmology study led by Dr. Anton Kolomeyer found that patients undergoing incisional eye surgery filled opioid prescriptions more frequently in 2014‑2016 than in 2000‑2001. The analysis showed higher prescribing rates for trauma, pediatric, and extensive procedures such...
Procedural Notes Aren’t Generic Data—Misclassify at Your Peril
Procedural notes drive safety, throughput, coding, and revenue. Treating them like generic data is a costly mistake. Important read from @Provationmed on the hidden risks CIOs face when changing clinical documentation platforms. https://t.co/WahjLaUB6N #ClinDoc #HITSM
Supreme Court Declines to Hear Drugmakers' Challenge to Price Negotiations
The U.S. Supreme Court declined to hear appeals from six major drug manufacturers seeking to block the Medicare Drug Price Negotiation Program. The decision leaves lower‑court rulings that uphold the program intact, allowing the government to continue negotiating prices for...
MSD's Sac-TMT Delivers in First Phase 3 Readout
Merck (MSD) reported that its TROP2‑targeting antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT), licensed from China’s Kelun‑Biotech, improved progression‑free and overall survival in a phase 3 trial for advanced or recurrent endometrial cancer. The TroFuse‑005 readout marks the first pivotal data for sac‑TMT...
Adenine Base Editing Demonstrates Profound Impact on Rare Disease
Researchers at The Jackson Laboratory used adenine base editing to repair the SCN1A R613X mutation that causes Dravet syndrome in mice. A single brain injection corrected roughly 60% of the defective DNA, restoring normal gene expression and dramatically reducing seizures....
How a Funding Pause Derailed an Artificial Heart for Babies
James Antaki, a biomedical engineer at Cornell, was on the brink of delivering a battery‑size artificial heart for infants when the Trump administration froze over $1 billion in federal research funding, forcing his lab to shut down and staff to be...
FDA Clears Next-Gen Contrast Management System for the Cath Lab
Acist Medical Systems, a Bracco subsidiary, received FDA clearance for its Acist Pro Diagnostic System, a next‑generation contrast management platform for cardiac catheterization labs. The system, already launched in Japan and Europe, offers real‑time contrast tracking, customizable presets, and on‑screen...
Children’s Mental Health Visits Have Shot Up, Research Shows
A new JAMA Network Open study of 1.8 million Massachusetts children shows pediatric mental‑health visits climbed from 5.7% of all visits in 2014 to 9.7% in 2023. Anxiety appointments surged more than 250%, rising from 1.7% to 6.1% of visits. Smaller...
Quantori and Knowledge3 Announce Co-Marketing Partnership to Advance Knowledge-Driven AI in Life Sciences
Quantori, a digital transformation firm for life sciences, announced a co‑marketing partnership with Knowledge3, a specialist in knowledge graphs and FAIR data. The alliance blends Quantori’s AI and scientific software expertise with Knowledge3’s knowledge‑first architecture to create scalable, context‑aware AI...
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
The FDA has granted approval to Baxfendy (baxdrostat), AstraZeneca’s first aldosterone synthase inhibitor, for adults whose blood pressure remains uncontrolled despite existing therapies. The approval is based on the phase 3 BaxHTN trial, where a 2 mg dose lowered systolic pressure by...
Kaleidex Announces Major New MedTech Manufacturing Facility in Yorkshire
Kaleidex Group announced Kaleidex One, a 60,000 sq ft precision‑manufacturing hub in Yorkshire slated for a 2027 launch. The "Factory of the Future" will combine clean‑room assembly, rapid prototyping, automation and end‑to‑end production services for global OEMs and emerging MedTech firms. It...
Verbal Beginnings to Expand in Maryland with New Early Intervention Autism Center in Lanham, MD
Verbal Beginnings is opening its ninth Early Intervention Autism Center in Lanham, Maryland, slated for August 2026. The facility will serve children ages 1‑5 across Prince George’s County, offering center‑based Applied Behavior Analysis alongside Speech‑Language Pathology, Occupational Therapy, and parent‑training...
Høeg Fired in Latest FDA Shakeup; 20 People Die After Taking Amgen Drug
The FDA announced a leadership overhaul, firing acting CDER director Tracy Beth Høeg and installing Michael Davis as acting head, while Karim Mikhail now leads CBER. In Japan, 20 patients died after receiving Amgen’s rare‑disease drug Tavneos, prompting a warning and an existing U.S....
Merck's ADC Sac-TMT Gets Its First Global Phase 3 Win Ahead of Schedule
Merck and China‑based Kelun‑Biotech announced that their experimental antibody‑drug conjugate sac‑TMT achieved its primary endpoint in a global Phase 3 trial, completing ahead of schedule. The study enrolled roughly 650 patients with advanced solid tumours across 12 countries and demonstrated a...
Our AI Wearables Are “Changing the Game” For Disabled People
Meta unveiled a suite of new AI‑powered features for its Ray‑Ban and Oakley smart glasses, aimed at expanding independence for people with disabilities. The rollout adds hands‑free group calling with Be My Eyes, voice‑only call controls, one‑touch shortcuts, and real‑time...
Cambridge-Derived Brain Health Company Prema Cognition Closes Oversubscribed Funding Round to Advance Early Dementia Detection
Prema Cognition, a Cambridge‑derived digital health firm, closed an oversubscribed £550,000 (~$700,000) funding round led by SFC Capital, surpassing its £500,000 target. The capital will expand clinical datasets, accelerate regulatory work, and drive global rollout of its PREMAZ platform, which...
AI Uses One MRI and Demographics to Forecast Alzheimer’s Cognition
A single MRI + demographics + AI predicts current and future cognitive scores and outcomes for Alzheimer’s disease https://t.co/9Mm3kOCI8L
Sutter Health Strengthens Maternal Care Through Innovation and Connection
Sutter Health launched a systemwide maternal‑care initiative that aligns evidence‑based protocols, data dashboards, and multidisciplinary collaboration across its 16 labor‑and‑delivery sites. By expanding certified nurse‑midwife access, integrating doula support, and scaling group prenatal care, the health system increased CNM‑delivered births...
Sotatercept Reduced Morbidity in CTD-PAH Analysis: Rogerio Souza, MD, PhD
A pooled analysis of the phase‑3 STELLAR, ZENITH and HYPERION trials shows that sotatercept significantly lowers the risk of first major morbidity or mortality events in patients with connective tissue disease‑associated pulmonary arterial hypertension (CTD‑PAH). The benefit persisted despite most...
Once‑night Pill Proves Effective for Severe Sleep Apnea
A once a night pill for severe obstructive sleep apnea effective in a Phase 3 randomized trial https://t.co/zq2Ew65WHK https://t.co/ovQEh7taeN https://t.co/N8vXzYincy
FDA Approves Baxdrostat for Inadequately Controlled Hypertension
AstraZeneca’s Baxdrostat (Baxfendy) received FDA approval as the first aldosterone synthase inhibitor for hypertension in the United States. The drug is indicated for patients whose blood pressure remains uncontrolled despite taking at least two other antihypertensive agents. Phase III trials (BaxHTN...
Why Real-World Evidence Is Becoming the Missing Link Between Innovation and Patient Care in Oncology
Oncology’s rapid innovation—targeted therapies, immunotherapies, and precision medicine—outpaces the ability of traditional clinical trials to predict real‑world performance. Real‑world evidence (RWE) bridges this gap by using longitudinal, clinically rich data to show how treatments work across diverse patient populations and...
Behavioral Science: The Missing Link in Remote Monitoring
Remote patient monitoring (RPM) programs often falter not because the technology fails, but because they ignore how patients actually behave. Behavioral science offers proven design tactics—smart defaults, loss framing, habit linking, adaptive messaging, and temporal landmarks—that can dramatically lift engagement....
Cognitive Overload in Cardiac Arrest Is a Human Problem
Dr. Michael Peck highlights that clinicians managing cardiac arrests still depend heavily on memory, leading to cognitive overload during high‑stress resuscitations. Over three decades of technological advances have not addressed this human limitation, prompting him and an emergency‑medicine co‑founder to...
Healthcare Reimbursement: Succeeding Under Value-Based and FFS Payment
Healthcare reimbursement models—fee‑for‑service, DRGs, capitation, and value‑based care—shape hospital cash flow and risk exposure. Providers must master each model’s incentive structure and execute a five‑step claims process, from documentation to patient billing. Errors in coding, claim submission, or payer adjudication...
What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape
PSMA‑targeted radioligand therapy, exemplified by lutetium‑177 vipivotide tetraxetan (Pluvicto), is now a standard option for metastatic castration‑resistant prostate cancer. However, response durability is limited, with fewer than half of patients achieving meaningful benefit and most eventually progressing. The authors highlight...
Atropos Health and Guidehouse Launch Point-of-Care Clinical Decision Support Solution
Atropos Health and consulting firm Guidehouse have launched a joint clinical decision support (CDS) platform that embeds predictive AI models directly into electronic health records. The solution uses aggregated claims and EHR data to stratify patients and deliver real‑time alerts...
Novartis' Pluvicto Cuts PSA Progression Risk in Phase 3 Prostate Cancer Trial
Novartis announced that its radioligand therapy Pluvicto, when added to standard of care, reduced the risk of prostate-specific antigen progression in the Phase III PSMAddition trial for PSMA‑positive metastatic hormone‑sensitive prostate cancer. The data were unveiled at the American Urological Association...
Pittsburgh Researchers Develop Shelf-Stable Artificial Platelets to Stop Severe Bleeding
Researchers at the University of Pittsburgh, in partnership with Case Western Reserve and Haima Therapeutics, have created SynthoPlate, a freeze‑dried artificial platelet that reconstitutes with water to form a clotting agent. The quarter‑sized vial remains stable at room temperature for...
The Growing Need for Acupuncturists in Modern U.S. Healthcare
Chronic pain management in the U.S. is shifting toward non‑pharmacologic solutions, and acupuncture is emerging as a core component of integrative pain programs across hospitals and primary‑care networks. The American College of Physicians’ 2017 guideline now lists acupuncture as a...
Nanobiotix's Phase‑2 Lung Cancer Trial Shows 85.7% Response Rate
Nanobiotix S.A., with Johnson & Johnson as sponsor, presented Phase‑2 CONVERGE data showing an 85.7% overall response rate and 57.1% complete response in seven stage III inoperable NSCLC patients, suggesting the nanoparticle radioenhancer NBTXR3 could improve outcomes when combined with chemoradiotherapy...
Hawaii Passes HB 1804 to Forge Public‑Private Long‑Term Care Funding Model
The Hawaii Legislature approved House Bill 1804, mandating the Executive Office on Aging to develop an actuarially sound, affordable mix of public and private funding for long‑term care. The move revives a four‑decade effort to protect middle‑income families from soaring...
2025 Gene Therapy Sales: New Top 10 Entrants Revealed
18May: Which were the Top 10 Best-Selling Gene Therapies based on 2025 sales? Which gene therapies made this year's list but missed last year's, and vice versa? Check out my latest A-List for @GENbio: https://t.co/pbUP8lI82X
Minnesota House Blocks 340B Hospital Discount Bill, Delivering Pharma Win
Minnesota House Republicans voted to kill a bill that would have forced drugmakers to honor all hospital‑pharmacy contracts under the federal 340B program, despite a 42‑24 Senate approval. The defeat hands a win to pharmaceutical lobbyists and stalls a key...
The Ebola Emergency Shines a Light on the Urgent Need for New Vaccines
The Democratic Republic of Congo and Uganda are facing a Bundibugyo Ebola outbreak, with the U.S. CDC reporting 336 suspected cases and 88 deaths as of 17 May. The WHO declared a public‑health emergency of international concern, but its response is...
Healthcare Doesn’t Need More Companies Managing Unnecessary Costs – It Needs a System Designed to Eliminate Them
The U.S. spends roughly $5.3 trillion on healthcare, with about 20% tied up in administrative waste. Most cost‑containment firms still operate on a percent‑of‑savings model, taking 15‑30% of negotiated reductions and rewarding higher bills. Navin Nagiah argues that this misaligned incentive...
How Advanced Analytics Partnerships Enhance the Biopharma Value Chain
Strategic biopharma alliances are increasingly embedding multimodal AI across the entire drug‑development pipeline. Partnerships leverage foundation models to sharpen biomarker discovery and patient selection for complex modalities such as antibody‑drug conjugates. Large‑scale genomic and clinical datasets enable virtual cell modeling...
Do Wall Street Analysts Like Welltower Stock?
Welltower Inc., a $150.9 billion healthcare REIT, posted a 45.5% stock surge over the past year, outpacing the S&P 500 and its real‑estate peers. First‑quarter 2026 results showed normalized FFO of $1.47 per share, a 23% year‑over‑year rise, and revenue of $3.35 billion,...
Roche’s $1.05 B PathAI Deal Highlights Massachusetts AI Hub Momentum
Roche agreed to buy Boston‑based PathAI for $750 million upfront, with a potential $300 million earn‑out, a deal valued at up to $1.05 billion. The transaction, praised by coalition members including Whoop, signals deepening venture capital confidence in Massachusetts’ AI cluster.
FDA Approves Enhertu for Neoadjuvant and Adjuvant HER2‑Positive Early Breast Cancer
The U.S. Food and Drug Administration has approved Enhertu (fam‑trastuzumab deruxtecan‑nxki) for two new HER2‑positive early‑breast‑cancer indications – neoadjuvant treatment of stage 2‑3 disease and adjuvant therapy for patients with residual invasive disease after standard therapy. The approvals rest on phase 3...